Palonosetron News and Research

RSS
Palonosetron is a second-generation 5-hydroxytryptamine 3 (5-HT3)-receptor antagonist that has shown better efficacy than ondansetron and dolasetron in preventing chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately emetogenic chemotherapy, and similar efficacy to ondansetron in preventing CINV in patients receiving highly emetogenic chemotherapy.
Palonosetron effective anti-emetic for paediatric chemotherapy patients

Palonosetron effective anti-emetic for paediatric chemotherapy patients

Helsinn's Akynzeo for CINV prevention receives EC approval

Helsinn's Akynzeo for CINV prevention receives EC approval

Helsinn launches Helsinn Integrative Care division at ASCO Annual Meeting

Helsinn launches Helsinn Integrative Care division at ASCO Annual Meeting

Helsinn Group announces European approval of ALOXI (palonosetron HCl) injection for paediatric use

Helsinn Group announces European approval of ALOXI (palonosetron HCl) injection for paediatric use

STA, Helsinn announce approval of AKYNZEO for prevention of chemotherapy-induced CINV

STA, Helsinn announce approval of AKYNZEO for prevention of chemotherapy-induced CINV

Eisai, Helsinn Group announce FDA approval of AKYNZEO for prevention of CINV

Eisai, Helsinn Group announce FDA approval of AKYNZEO for prevention of CINV

ALOXI injection receives FDA approval for prevention of nausea, vomiting associated with cancer chemotherapy

ALOXI injection receives FDA approval for prevention of nausea, vomiting associated with cancer chemotherapy

Helsinn, Mundipharma sign distribution and license agreement for investigational therapy

Helsinn, Mundipharma sign distribution and license agreement for investigational therapy

STA announces results from ABRAXANE plus gemcitabine phase III trial on pancreatic cancer

STA announces results from ABRAXANE plus gemcitabine phase III trial on pancreatic cancer

Risk model predicts illness after ambulatory surgery

Risk model predicts illness after ambulatory surgery

A.P. Pharma announces additional data from APF530 Phase 3 study on CINV

A.P. Pharma announces additional data from APF530 Phase 3 study on CINV

Results from A.P. Pharma’s APF530 Phase 3 trial on CINV

Results from A.P. Pharma’s APF530 Phase 3 trial on CINV

Helsinn commences Netupitant/Palonosetron Phase III combination study in CINV

Helsinn commences Netupitant/Palonosetron Phase III combination study in CINV

New palonosetron-aprepitant trial data on chemotherapy induced nausea, vomiting presented at EHA

New palonosetron-aprepitant trial data on chemotherapy induced nausea, vomiting presented at EHA

Simcere subsidiary receives Chinese SFDA approval to manufacture and market Palonosetron

Simcere subsidiary receives Chinese SFDA approval to manufacture and market Palonosetron

New Zealand MEDSAFE approves ABRAXANE for metastatic breast cancer

New Zealand MEDSAFE approves ABRAXANE for metastatic breast cancer

Helsinn Healthcare S.A., Eisai announce signing of licensing agreement

Helsinn Healthcare S.A., Eisai announce signing of licensing agreement

TESARO secures $60 million in start-up funding to acquire, develop and commercialize cancer therapeutics

TESARO secures $60 million in start-up funding to acquire, develop and commercialize cancer therapeutics

A.P. Pharma's NDA for APF530 in prevention of CINV: FDA issues Complete Response Letter

A.P. Pharma's NDA for APF530 in prevention of CINV: FDA issues Complete Response Letter

A.P. Pharma announces financial results for its third quarter ended September 30, 2009

A.P. Pharma announces financial results for its third quarter ended September 30, 2009